Diabetic Nephropathy - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 200 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Nephropathy - Overview 9
Diabetic Nephropathy - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Diabetic Nephropathy - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Diabetic Nephropathy - Companies Involved in Therapeutics Development 31
AbbVie Inc 31
Allergan Plc 31
Antisense Therapeutics Ltd 32
Aptevo Therapeutics Inc 32
Araim Pharmaceuticals Inc 33
Arena Pharmaceuticals Inc 33
Astellas Pharma Inc 34
AstraZeneca Plc 34
Bayer AG 35
BLR Bio LLC 35
Boehringer Ingelheim GmbH 36
Cellmid Ltd 36
ChemoCentryx Inc 37
CSL Ltd 37
Daiichi Sankyo Company Ltd 38
DiaMedica Therapeutics Inc 38
Dynamis Therapeutics Inc 39
Galectin Therapeutics Inc 39
GenKyoTex SA 40
Gilead Sciences Inc 40
GNI Group Ltd 41
Islet Sciences Inc 41
Jenrin Discovery Inc 42
Johnson & Johnson 42
Mallinckrodt Plc 43
Mesoblast Ltd 43
Mitsubishi Tanabe Pharma Corp 44
MorphoSys AG 44
Novartis AG 45
Noxxon Pharma AG 45
Omeros Corp 46
PhiloGene Inc 46
PhytoHealth Corp 47
ProMetic Life Sciences Inc 47
RegenMedTX LLC 48
Serodus ASA 48
Teijin Pharma Ltd 49
Theravance Biopharma Inc 49
Variant Pharmaceuticals Inc 50
Vascular Pharmaceuticals Inc 50
Vicore Pharma AB 50
XORTX Pharma Corp 51
Diabetic Nephropathy - Drug Profiles 52
11-RVIVIT - Drug Profile 52
A-717 - Drug Profile 53
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 54
APD-371 - Drug Profile 55
APX-115 - Drug Profile 56
ASP-8232 - Drug Profile 57
atesidorsen sodium - Drug Profile 58
atrasentan hydrochloride - Drug Profile 66
BI-703704 - Drug Profile 68
BL-5923 - Drug Profile 69
BLR-200 - Drug Profile 70
C-21 - Drug Profile 71
canagliflozin - Drug Profile 74
CCX-140 - Drug Profile 81
Cell Therapy for Chronic Kidney Disease and Metabolic Disorders - Drug Profile 85
cenicriviroc mesylate - Drug Profile 87
cibinetide - Drug Profile 95
corticotropin - Drug Profile 98
CSL-346 - Drug Profile 100
Cyndacel-M - Drug Profile 101
DM-299 - Drug Profile 103
Drugs for Diabetic Nephropathy - Drug Profile 104
DT-23552 - Drug Profile 105
DYN-12 - Drug Profile 106
emapticap pegol - Drug Profile 108
esaxerenone - Drug Profile 111
finerenone - Drug Profile 114
GKT-136901 - Drug Profile 116
GKT-831 - Drug Profile 117
GLY-230 - Drug Profile 120
GRMD-02 - Drug Profile 121
GS-444217 - Drug Profile 134
IP-9 - Drug Profile 135
JD-5037 - Drug Profile 136
JNJ-39933673 - Drug Profile 137
MG-132 - Drug Profile 138
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 139
MOR-107 - Drug Profile 141
MPC-300IV - Drug Profile 142
MT-3995 - Drug Profile 148
Orbcel-M - Drug Profile 149
oxypurinol - Drug Profile 150
PBI-4050 - Drug Profile 151
PBI-4425 - Drug Profile 158
PBI-4547 - Drug Profile 159
PHN-033 - Drug Profile 160
pirfenidone - Drug Profile 161
Recombinant Protein to Antagonize VEGFR-2 for Diabetic Nephropathy and Oncology - Drug Profile 163
SER-150 - Drug Profile 164
Small Molecules for Diabetic Nephropathy - Drug Profile 167
Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy - Drug Profile 168
SP-20202 - Drug Profile 169
TBE-31 - Drug Profile 170
TD-0714 - Drug Profile 171
TD-1439 - Drug Profile 173
TMX-049 - Drug Profile 174
TNFR x TWEAKR - Drug Profile 175
VAR-400 - Drug Profile 176
VPI-2690B - Drug Profile 177
VS-105 - Drug Profile 178
Wnt-001 - Drug Profile 179
XRX-108 - Drug Profile 180
XRX-221 - Drug Profile 181
Diabetic Nephropathy - Dormant Projects 182
Diabetic Nephropathy - Discontinued Products 184
Diabetic Nephropathy - Product Development Milestones 185
Featured News & Press Releases 185
Appendix 195
Methodology 195
Coverage 195
Secondary Research 195
Primary Research 195
Expert Panel Validation 195
Contact Us 195
Disclaimer 196

List of Tables

Number of Products under Development for Diabetic Nephropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2017
Diabetic Nephropathy - Pipeline by Allergan Plc, H1 2017
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2017
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2017
Diabetic Nephropathy - Pipeline by BLR Bio LLC, H1 2017
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Diabetic Nephropathy - Pipeline by Cellmid Ltd, H1 2017
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H1 2017
Diabetic Nephropathy - Pipeline by CSL Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by GenKyoTex SA, H1 2017
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by GNI Group Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by Jenrin Discovery Inc, H1 2017
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2017
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2017
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2017
Diabetic Nephropathy - Pipeline by Novartis AG, H1 2017
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2017
Diabetic Nephropathy - Pipeline by Omeros Corp, H1 2017
Diabetic Nephropathy - Pipeline by PhiloGene Inc, H1 2017
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H1 2017
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by RegenMedTX LLC, H1 2017
Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2017
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by Variant Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2017
Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017 (Contd..1), H1 2017
Diabetic Nephropathy - Discontinued Products, H1 2017